Back to Search
Start Over
Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis.
- Source :
-
Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2021 Jun; Vol. 73 (6), pp. 1086-1087. Date of Electronic Publication: 2021 Apr 16. - Publication Year :
- 2021
- Subjects :
- Adalimumab therapeutic use
Aged
Arthritis, Rheumatoid genetics
Biological Assay
Etanercept therapeutic use
Humans
Middle Aged
Prognosis
Protein Tyrosine Phosphatase, Non-Receptor Type 22 genetics
Reproducibility of Results
Treatment Outcome
Tumor Necrosis Factor Inhibitors therapeutic use
Adalimumab pharmacology
Arthritis, Rheumatoid drug therapy
Etanercept pharmacology
Protein Tyrosine Phosphatase, Non-Receptor Type 22 drug effects
Transcriptome drug effects
Tumor Necrosis Factor Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 2326-5205
- Volume :
- 73
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Arthritis & rheumatology (Hoboken, N.J.)
- Publication Type :
- Academic Journal
- Accession number :
- 33426780
- Full Text :
- https://doi.org/10.1002/art.41645